Talem and Libera Bio partner for discovery of AI-driven antibodies

Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio.

The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.

It will use the LENSai Full Suite of Integrated Intelligence Technology from Immunoprecise Antibodies’ subsidiary BioStrand with the Multifunctional Polymeric Nanocapsules (MPN Technology) of Libera Bio.

The MPN Technology provides an elegant way for delivering antibodies inside tumour cells.

The nanocapsules are designed specifically around the antibodies’ physicochemical properties, for protecting them from degradation in the bloodstream.

Additionally, MPNs can provide other biologic modalities or combinations of a biologic as well as a small molecule in the same nanocapsule.

They deliver the compounds through a cell membrane and to intracellular targets.

Under the collaboration, Libera Bio and Talem Therapeutics will together develop new antibodies for use with MPN delivery.

These antibodies will be provided to pharma companies for conducting late-stage development and marketing.

They will investigate two intracellular targets with high unmet patient requirements for providing options to the oncologists who treat them.

Immunoprecise Antibodies CEO and president Dr Jennifer Bath said: “As we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the ‘Holy Grail’ in oncology.

“Libera Bio’s ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously ‘undruggable’ targets is an exciting development that has the potential to transform the way we treat cancer.”